-
Mashup Score: 0Corticosteroid Responsiveness Following Mepolizumab in Severe Eosinophilic Asthma—A Randomized, Placebo-Controlled Crossover Trial (MAPLE) - 2 year(s) ago
Mepolizumab inhibits IL-5 activity and reduces exacerbation frequency and maintenance oral corticosteroid (OCS) dosage in patients with severe eosinophilic asthma (SEA). Some patients remain dependent on OCS despite anti–IL-5 treatment, suggesting residual corticosteroid-responsive mechanisms.
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0
Transient increases in blood eosinophil counts have been observed in dupilumab clinical trials.
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0High Prevalence of Gastrointestinal Symptoms and Undiagnosed Eosinophilic Esophagitis among Allergic Adults - 2 year(s) ago
Adults with atopic disease seen in a tertiary care Allergy Clinic report high rates of solid food dysphagia, food impaction and other abdominal symptoms. These findings suggest that EoE may be several times more prevalent in patients with allergic disease than the general population.
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0Economic impact of anti-IL-5 agents in patients with severe eosinophilic asthma: a population-based cohort study - 2 year(s) ago
Article InfoPublication HistoryAccepted: July 21, 2022Received in revised form: July 20, 2022Received: May 16, 2022Publication stageIn Press Journal Pre-ProofFootnotesConflicts of Interest.GC received research support from the European Community (EC), the Italian Medicines Agency (AIFA), and the Italian Ministry of Education,…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 3Corticosteroid responsiveness following mepolizumab in severe eosinophilic asthma - a randomised, placebo-controlled crossover trial [MAPLE] - 2 year(s) ago
Mepolizumab inhibits interleukin-5 (IL-5) activity, reduces exacerbation frequency and maintenance oral corticosteroid (OCS) dosage in patients with severe eosinophilic asthma (SEA). Some patients remain dependent on OCS despite anti-IL-5 treatment suggesting residual corticosteroid responsive mechanisms.
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 3
Background Eosinophilic oesophagitis (EoE) is an increasingly common cause of dysphagia in both children and adults, as well as one of the most prevalent oesophageal diseases with a significant impact on physical health and quality of life. We have provided a single comprehensive guideline for both paediatric and adult gastroenterologists on current best practice for the evaluation and management…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 0The Broad Spectrum of Eosinophilic Disorders - 2 year(s) ago
Eosinophilia is encountered frequently in children and adults and has a broad differential diagnosis that includes hematologic, infectious, immunologic, and allergic disorders. Eosinophilia may be primary (due to abnormalities in the myeloid lineages) or secondary (driven by mediators produced by nonmyeloid cells), mild or marked, with or without clinical manifestations, and transient or…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 3Controversies in Allergy: The Potential Role of Biologics as First-Line Therapy in Eosinophilic Disorders - 2 year(s) ago
With advances in understanding the role of eosinophils in disease pathogenesis, particularly in the airways, gastrointestinal tract, and skin, targeting eosinophils or the cytokines that lead to their production, activation, and survival has become an increasingly pursued therapeutic approach. Newly developed biologic agents target eosinophils directly, other cells interacting with or activating…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 3Real-World Effectiveness of Reslizumab in Patients with Severe Eosinophilic Asthma – “First Initiators” and “Switchers” - 2 year(s) ago
Reslizumab, a biologic targeting interleukin-5 has been shown to reduce asthma exacerbations and maintenance oral corticosteroid (OCS) use in randomized controlled trials and pre-post studies in patients with severe eosinophilic asthma. However, real-world effectiveness data of reslizumab are scarce, and it is unknown whether reslizumab has added value after switching from another type-2 biologic.
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0Novel questionnaires for assessing signs and symptoms of eosinophilic esophagitis in children - 2 year(s) ago
Pediatric patients with eosinophilic esophagitis (EoE) experience heterogenous symptoms and patients’ age may preclude reliable self-report of symptoms.
Categories: Allergy-Immunology, Latest HeadlinesTweet
In Current Issue! #Corticosteroid #Responsiveness Following #Mepolizumab in #Severe #Eosinophilic #Asthma—A Randomized, Placebo-Controlled Crossover Trial ( #MAPLE) https://t.co/zvzVTrybPx https://t.co/UmrUJZmZPF